In a single-center study, we analyzed the outcomes of 66 patients with advanced hematological malignancies receiving two reduced-intensity conditioning regimens for allogeneic transplantation: fludarabine and low-dose TBI (flu/TBI, n ¼ 25), or fludarabine, antithymocyte globulin and BU (flu/ATG/BU, n ¼ 41). The selection criteria were based on the hypothesis that flu/TBI patients were expected to achieve autologous recovery in the event of non-engraftment. Sixty-three patients (95%) engrafted. Regimen-related mortality at day 100 and 1 year was 6 and 15%, respectively. With median follow-up of 50.4 months, survival did not differ by regimen. Multivariate analysis confirmed that the type of regimen did not affect relapse. In patients achieving full donor chimerism by day 30, those conditioned with flu/TBI showed greater overall survival (P ¼ 0.02). Engraftment failure occurred in two patients (3%), both of whom received flu/TBI. We conclude that conditioning with flu/TBI or flu/ATG/BU yields comparable survival and remission outcomes. By contrast to our hypothesis, patients receiving flu/TBI who subsequently failed engraftment did not achieve autologous recovery. Yet, rapid attainment of full donor chimerism after flu/TBI is associated with greater survival than after flu/ATG/BU. Further, larger prospective randomized studies are required to define the advantage of one regimen over the other.
Introduction
The paradox of allogeneic hematopoietic SCT as treatment for advanced hematological malignancies is well known. Patients most needful of the therapy are often least likely to tolerate it because of advanced age, medical comorbidity or declining reserves caused by earlier treatments. In traditional myeloablative allogeneic transplantation, there are two components to the therapeutic effect. First, a preparative regimen consisting of chemoradiotherapy or a chemotherapy combination is applied with the intent of cytoreducing tumor and suppressing the host's immune system to allow engraftment of the donor hematopoietic system. Second, the engrafted donor's immune system recognizes host tumor as foreign and mounts an immune attack thought to be responsible for long-term disease control and cure. In the last decade, work has advanced to emphasize the second component of therapy while reducing the intensity of the first.
A true non-myeloablative or reduced-intensity approach uses a preparative regimen that employs a potent temporary host immunosuppression coupled with novel postgrafting immunosuppression with little ability to debulk tumors. 1 This approach relies on graft-versus-tumor 2 immune function to cure disease and is characterized in its mildest form by a regimen of low-dose TBI alone; 3 whereas the addition of fludarabine to this program reduces the incidence of graft failure. The second approach incorporates the use of a traditional alkylating agent at half its myeloablative dose used in conjunction with immunosuppressive agents. 4 This provides broad spectrum antitumor activity before the onset of salutary graftversus-tumor effects. 5 A lowered dose of chemotherapy is believed to reduce the incidence of regimen-related toxicity.
Despite the number of reduced-intensity regimens available, the advantage of one over the other is not known as protocols vary according to the center. As a single-center prospective phase II clinical trial, we selected a low-dose TBI or non-TBI based regimen based on the hypothesis that patients receiving low-dose TBI can achieve autologous recovery in the event of graft failure or waning donor chimerism. Conversely, those conditioned with flu/ ATG/BU may not be able to achieve autologous recovery because of the higher intensity of this regimen. Therefore, on the basis of our hypothesis, the latter regimen was chosen for patients with an available autologous stem cell backup or a readily available allogeneic sibling donor. Study end points included issues of engraftment, chimerism, GVHD and patient outcomes.
Patients and methods

Eligibility criteria
Patients with hematological malignancies (n ¼ 66) who were referred to the Shands-University of Florida Bone Marrow Transplant Program were considered for this phase II protocol if they were over 55 years old (n ¼ 33), had significant comorbidities (n ¼ 9), or had received earlier high-dose therapy and autologous stem cells (n ¼ 24). Each patient was presented in the weekly multidisciplinary transplant team meeting and eligibility was discussed and confirmed. Patients with sibling or unrelated donors were considered, each matched for human leukocyte Ag-A (HLA-A), -B and -DRb1. One patient had a mismatch at HLA-B, whereas the remainder showed a 6 of 6 degree of concordance as determined by high-resolution DNA typing.
Patients were excluded from the study if they had rapidly progressive disease, were pregnant, had HIV, had a bilirubin 43, creatinine clearance o30 ml/min or a cardiac ejection fraction o35%.
Patient characteristics
A total of 66 patients were enrolled and transplanted on this protocol between 6 July 2000 and 17 March 2006. Ten patients received BM grafts (from unrelated donors) and the remainder received G-CSF-mobilized PBSC products (31 from siblings and 25 from unrelated donors). Patient and disease characteristics are detailed in Table 1 . A total of 30 patients were female and 36 were male. Their median age was 55 years (range 17-70 years). Patient diagnoses were AML (n ¼ 21), ALL (n ¼ 4), AML (n ¼ 1), CLL (n ¼ 4), myelodysplastic sydrome (n ¼ 10), multiple myeloma (n ¼ 12), non-Hodgkin's lymphoma (n ¼ 11) and Hodgkin's lymphoma (n ¼ 3). The relapse risk (low, standard or high) was based on disease type and status at the time of transplant, and determined according to an earlier study by Kahl et al.
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Conditioning regimens and post-grafting immunosuppression A total of 25 patients received a regimen 3 ('flu/TBI') consisting of fludarabine (30 mg/kg/day i.v.) on days À4, À3 and À2 and 2 Gy of TBI on day 0 (Figure 1a ). Immunosuppressive therapy with oral tacrolimus (0.06 mg/kg p.o. twice a day) was started on day À3, and mycophenolate mofetil (15 mg/kg p.o. twice a day for related donor transplants and three times a day for unrelated donor transplants) was started 4-6 h after transplant on day 0. For patients with related donors with no evidence of GVHD, mycophenolate mofetil was discontinued at day þ 28 without taper and tacrolimus was tapered at day þ 60 over 8 weeks. In patients with unrelated donors with no evidence of GVHD, mycophenolate mofetil was tapered at day 40 over 8 weeks and tacrolimus was tapered at day 100 over 8 weeks.
A total of 41 patients received a regimen ('flu/ATG/BU') consisting of fludarabine (30 mg/kg/day i.v.) on days À7 to À2 and rabbit ATG (Thymoglobulin, Genzyme, Cambridge, MA, USA) (n ¼ 18) 1.5 mg/kg/day i.v; or equine ATG (n ¼ 23) 10 mg/kg/day i.v. over 4 h on days À6 to À3 as initially described by Slavin et al., 5 and BU 1 mg/kg/dose p.o. every 6 h on days À4 and À3 (Figure 1b) . Immunosuppressive therapy with tacrolimus (0.06 mg/kg p.o. twice a day) was started on day À3. In patients with related donors and no GVHD, tacrolimus was tapered at day þ 60 over 8 weeks. In patients with unrelated donors and no GVHD, tacrolimus was tapered at day 100 over 8 weeks.
For patients at high risk of graft rejection, including recipients of an unrelated donor transplant without autologous backup, the flu/TBI regimen was chosen. In general, this approach was also considered first for patients without neoplastic disease or with minimal disease burden. The remainder of patients received more intensive immunosuppression with flu/ATG/BU conditioning.
Chimerism analysis and donor lymphocyte infusions
For chimerism analysis, nucleated cells were isolated from the marrow, and T/B lymphocytes and granulocytes from the peripheral blood by flow cytometry on days 30, 60, 90, Abbreviations: ATG ¼ antithymocyte globulin; flu ¼ fludarabine.
TBI vs non-TBI reduced-intensity conditioning C Cable et al 180, 270 and 365 and then yearly post-transplant. Percentages of donor-host chimerism for recipients of sex-mismatched allogeneic transplant were evaluated by FISH for X and Y chromosomes, whereas for those recipients of sex-matched allogeneic transplant, PCR-based amplification of STR sequences unique to donors and recipients was performed. Full donor chimerism was defined as greater than 95% donor cells.
In the absence of manifestations of severe GVHD, persistent or progressive disease was treated by the rapid discontinuation of immunosuppressive therapy to induce graft-versus-tumor effects. For relapse or failing chimerism, donor lymphocyte infusions (DLI) were given with calculated CD3 þ cell dose (between 5 Â 10 6 CD3 þ /kg and 5 Â 10 8 CD3 þ /kg), either with or without cytoreductive chemotherapy.
Study end points and definitions
Data were analyzed as of 31 July 2007. The primary study end points were sustained allogeneic engraftment, infectious complications, achievement of CR, development of acute or chronic GVHD and chimerism.
Acute GVHD was defined by clinical manifestations even if noted after 100 days based on the current published literature citing delay in GVHD onset after non-myeloablative allogeneic transplantation. 7 Engraftment day was defined as the first of three consecutive days for which ANC recovered to above 0.5 Â 10 9 cells/l. For patients whose ANC did not decrease below this point, the day of ANC nadir with subsequent rise was defined as the engraftment day.
Statistical analysis
Kaplan-Meier plots were used to assess time to relapse, time to death and time to acute and chronic GVHD. The models for time to relapse, acute GVHD and chronic GVHD censored observations at the time of death and last patient follow-up. The model for death only censored observations at the last patient follow-up. A Cox proportional hazard model was used to assess the time to relapse adjusted for conditioning type, donor source and transplant type (BM or PBSCs). Models were also generated for survival limited to patients who achieved full donor chimerism at 30 days. Univariate analyses testing the association between conditioning type and patient demographic characteristics were conducted with w 2 -tests for categorical variables and Mann-Whitney tests for continuous variables. All analyses were conducted using SAS (v.9.1, SAS Institute Inc., Cary, NC, USA). TBI vs non-TBI reduced-intensity conditioning C Cable et al
Results
Toxicities
Incidences of grade III and IV toxicities as defined per the NCI guidelines were as follows: cardiac (9%), pulmonary (1.5%), hepatic (1.5%), neurological (3%), gastrointestinal (6%), renal (15%) and hemorrhagical (4.5%). Neutropenic infection (excluding febrile neutropenia with no clinical source of infection) occurred in eight patients (12%) and non-neutropenic infection occurred in 21 patients (32%).
Engraftment and graft failure
One patient conditioned with flu/ATG/BU expired at 19 days post-transplant from an intracranial hemorrhage and was not evaluable for engraftment. Initial granulocyte engraftment was observed in 63 out of the remaining 65 patients (97%), with median time to engraft at 18 days (range 4-37). The two patients failing to engraft received conditioning with flu/TBI and unrelated PBSC allografts, one of whom had a high-resolution mismatch at HLA-B. Three additional patients had delayed graft rejection at days 67, 112 and 113 on taper of immunosuppression as indicated for persistent mixed chimerism, and did not achieve autologous recovery by days 76, 138 and 203, respectively. Subsequently, all three patients were retransplanted with intermediate intensity conditioning. Of the 60 patients with durable engraftment, the median duration of neutropenia was 8.5 days (range, 0-53 days).
GVHD and infectious complications
Acute GVHD (grades II-IV) developed in 28 patients (42%), with a median onset of 32 days (range, 13-110 days). The cumulative incidence of acute GVHD was 41% (Figure 2a ). Chronic GVHD developed in 35 patients (53%), with a median onset of 134 days (range, 100-438 days). The cumulative incidence of chronic GVHD was 68% (Figure 2b ). A total of 22 patients (33%) developed CMV viremia. Of these, three patients progressed to CMV disease (one fatal pneumonia, two non-fatal colitis). Two patients developed adenovirus infection and one patient developed respiratory syncytial virus pneumonia. Ten patients developed probable or proven invasive fungal infections. One patient developed post-transplant lymphoproliferative disease.
Survival, relapse and regimen-related mortality A total of 58 patients (88%) were alive at day 100. Early regimen-related mortality was 6%, with four patients expiring within 100 days because of complications of either infection (n ¼ 3) or intracranial hemorrhage (n ¼ 1). All four patients received allografts from an unrelated donor, of which three were PBSCs and one was marrow. An additional four patients died within day 100 because of relapsed disease. Within 1-year post-transplant, six additional patients died because of non-relapse mortality. Regimen-related and non-relapse mortality were comparable between the two regimens at all time points. By Kaplan-Meier analysis, the proportion of patients alive at 1000 days was 42% (Figure 3a) , and the time to death did not differ by regimen (P ¼ 0.21) or by graft source (P ¼ 0.31) (data not shown).
A total of 32 (48%) patients relapsed. Relapse was comparable between conditioning groups (flu/ATG/BU, 59%; flu/TBI, 48%). By Kaplan-Meier analysis, relapsefree survival was 48% for all patients at 1000 days ( Figure 3b ) and also did not differ by regimen (data not shown). By multivariate analysis, no significant association was found between regimen type and relapse, in addition to other variables, such as patient age, graft source, donor relation and relapse risk ( Table 2) .
A total of 27 patients (41%) were alive and in CR (n ¼ 24) or PR (n ¼ 2); or with progressive disease (n ¼ 1) at last follow-up (median follow-up 50.4 months; range, 3.6-69 months).
Engraftment, delayed graft failure, DLIs and re-transplantation Engraftment failure occurred in 2 of 65 (3%) evaluable patients. Both received conditioning with flu/TBI and were recipients of unrelated donors.
The first non-engrafting patient was a 23-year-old female with AML in second CR who had received an earlier autologous stem cell transplant. The graft was PBSC, from a female unrelated donor with a B-Ag mismatch. Salvage allogeneic transplant with a pre-transplant immunosuppressive regimen of methylprednisone and ATG was not TBI vs non-TBI reduced-intensity conditioning C Cable et al successful and the patient died of diffuse adenoviral pneumonia on day 57. The second non-engrafting patient was a 38-year-old female with myelodysplastic syndrome and no earlier therapy except for growth factors. The graft was PBSC, from a male, matched and unrelated donor. The patient was given two G-CSF-mobilized DLI, the latter of the two given after conditioning with cytarabine and ATG. These attempts at DLI were unsuccessful and the patient succumbed to an invasive fungal infection on day 113.
For patients who engrafted, adoptive immunotherapy with calculated dose DLI, with or without additional chemotherapy, was used in 13 patients for relapse (n ¼ 8) or failing chimerism (n ¼ 5). Of the eight patients receiving DLI for relapse, three entered CR with this approach.
Of these, only one remained alive at the last follow-up. The remaining two patients succumbed to invasive fungal infections.
Salvage allogeneic transplant with intermediate intensity conditioning using cytidine arabinoside, CY and TBI 8 was attempted in three patients (all flu/TBI) with failing chimerism and subsequent delayed graft failure. Of these, two patients successfully engrafted and converted to full donor chimerism, and one achieved a CR and was alive and disease free at 45 months' follow-up.
Donor chimerism and survival
A total of 61 patients were evaluable for day 30 donor chimerism. The remaining five patients died early (n ¼ 4) or had relapsed disease (n ¼ 1) and were not evaluable. Of the patients evaluable, 62% attained full donor chimerism by this time and remained full donor through the last followup. By day 60, an additional three patients had achieved this status and one more by day 90. After day 90, an additional three patients had achieved durable full donor chimerism.
In patients achieving full donor chimerism by day 30, conditioning with flu/TBI was associated with greater overall survival as compared with flu/ATG/BU (P ¼ 0.02) by Kaplan-Meier analysis (data not shown). By multivariate analysis incorporating patient age, graft source, donor type and relapse risk, none of these variables was significantly associated with this difference in survival (data not shown).
Discussion
In this study, we prospectively measured the outcomes of two commonly used regimens with or without TBI in a single center and showed the feasibility of a reducedintensity conditioning approach in treating patients with advanced hematological malignancies. Clinically, both regimens had similar survival outcomes. In contrast with our hypothesis, we conclude that given a low graft failure rate with flu/ATG/BU, it does not seem to be necessary to include autologous stem cell backup as a criterion for determining eligibility for this regimen. In our original selection criteria, patients without autologous or readily available allogeneic sibling stem cell backup were assigned to receive flu/TBI because of the lesser intensity of this regimen as we hypothesized that these patients could TBI vs non-TBI reduced-intensity conditioning C Cable et al readily achieve autologous recovery in the event of graft failure. Surprisingly, both patients with primary graft failure were from the flu/TBI arm and did not achieve autologous recovery. What requires additional study is whether other factors such as earlier high-dose therapy and assessment of CD4 þ counts before transplant may enhance this determination, as the patient's degree of immunosuppression before transplant has a major influence on the likelihood of rejection. In general, patients tolerated both regimens well and survival data for this study are acceptable and well within the range of earlier reports.
3,5,9-13 The regimen-related mortality at day 100 (6%) is lower than for myeloablative transplantation for similar high-risk malignancy patients, considering the older population of patients (median age 55) and the number of unrelated donor transplants (n ¼ 35) in this series. Both of these factors traditionally carry a higher mortality rate.
Importantly, durable full donor chimerism after flu/TBI conditioning prolonged survival in our study, and flu/TBI patients achieving this status by day 30 were at a significant survival advantage as compared with flu/ATG/BU patients. Such observations illuminate the importance of assessing donor chimerism as a predictive tool for long-term survival outcomes after allogeneic transplantation. 14, 15 For patients with engraftment failure (n ¼ 2) or delayed graft rejection (n ¼ 3), attempts at re-establishing engraftment with DLI or fully myeloablative allogeneic transplant were successful in two out of five cases; yet only one of these patients achieved a durable complete response with this therapy. Although adoptive immunotherapy with DLI was used to treat progressive disease, it did not have significant salvage potential and only 1 of 14 patients (7%) obtained a curative response with this approach. The incidence of acute and chronic GVHD was within the expected limits for a patient cohort receiving reduced-intensity conditioning 16 and predominantly G-CSF-mobilized allografts. 17 In summary, this study prospectively measured the outcomes of TBI and non-TBI (ATG) based reducedintensity conditioning programs in a single center setting. A major conclusion is that we have modified our original hypothesis and inclusion criteria such that autologous stem cell backup is not required for conditioning with flu/ATG/ BU because of a low graft failure rate with this regimen. Therefore, where possible, patients may be considered for autologous stem cell backup collection if treated with this regimen, particularly if they have a mismatched or unavailable donor, or have had no earlier therapy. Lack of earlier therapy, as in patients with myelodysplastic syndrome, may indicate a stronger immune system and thus a higher likelihood of graft rejection. Our results show a statistically significant survival advantage for patients achieving durable donor chimerism by day 30 after flu/ TBI, as compared with flu/ATG/BU. Further prospective studies should be considered with larger numbers of matched patient groups to permit more powered statistical comparisons. Nevertheless, these results are promising in a patient population not eligible for the standard allogeneic transplantation.
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